Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review.

By contrast, the DI group showed a trend for better ORR ( Figure 3 ) and mPFS ( Figure 5A ) than those of the PI, DnI, and PnI groups (ORRs: 47.5%, 43.2%, 33.3%, and 40.5%, respectively, p = 0.799; and mPFS: 378, 190, 170, and 172 days, respectively, p = 0.115), though the differences were not statistically significant.

also in 53,322 other papers